Neurological and Hepatic Adverse Reactions to Watch for with Larotrectinib

Neurological and Hepatic Adverse Reactions to Watch for with Larotrectinib

During treatment with VITRAKVI, you need to pay special attention to two categories of potentially serious adverse reactions. The first is neurological symptoms: very common dizziness, as well as common paraesthesia of the extremities, such as tingling, numbness or a burning sensation in the hands and feet, or difficulty walking. These symptoms may indicate an impact on neurological function. The second is warning signs of liver injury: although the frequency is unknown, if you experience fatigue, right upper abdominal pain, loss of appetite, nausea and vomiting, accompanied by yellowing of the skin or eyes, increased easy bruising or bleeding, or dark urine, seek medical attention immediately, as this may indicate liver problems. If any of the above serious adverse reactions occur, your doctor will decide whether to reduce the dose, suspend treatment, or discontinue the medication entirely based on your condition.

Which Cancer Patients Are Eligible for Larotrectinib?

Larotrectinib is used to treat solid tumours caused by alterations in the NTRK gene (neurotrophic tyrosine receptor kinase gene) in adults, adolescents and children. Such genetic alterations are one of the causes of cancer development. This medicine is used only under specific conditions: the patient’s cancer is advanced or has spread to other parts of the body, or surgical resection of the tumour may lead to severe complications with no other satisfactory treatment options available. Before starting treatment, your doctor will perform a dedicated test to confirm the presence of NTRK gene alterations. The medicine is only indicated for patients with a positive test result.

How Does Larotrectinib Exert Its Anticancer Effect?

In patients with NTRK gene alterations, the abnormal gene instructs the body to produce an abnormal protein called a TRK fusion protein. This protein drives uncontrolled cell division and proliferation, ultimately leading to the development and progression of cancer. The active substance larotrectinib can precisely block the activity of the TRK fusion protein, thereby effectively slowing or even halting the growth of cancer cells. In addition, it may help shrink existing cancerous tumours. If you have any questions about the specific mechanism of action of the medicine or the reason for your doctor’s prescription, consult your doctor, pharmacist or nurse.